Blood: Long-term prognosis for the treatment of acetaminotaminal co-phenyramstininin

Condensate disease (CAD) refers to autoimmune diseases characterized by the concentration of red blood cells in the blood vessels at the end of the limb, the occurrence of skin microcirculation disorders, or autoimmune diseases characterized by mild hemolytic anemiathe study reviewed 232 patients with condensate in 24 centers in five countriesIn Norway and northern Italy, the study was almost population-basedThis study was the first to find a 4-fold difference in the prevalence of CAD in cold and warm climate areas (20 cases vs5 million) and morbidity (1.9 vs 0.48 cases/100,000 people per year)the average baseline baseline hemoglobin level was 9.3 g/dL, but 27% of patients had hemoglobin (8 g/dL)Through centralized biopsy assessment, it was found that the identification of typical characteristics of "CAD-related lymphatic disease" in the bone marrow increased significantlyCAD also appears to be associated with a mild increase in the risk of venous thromboembolismthis study included follow-up treatment follow-up, focusing on the long-term prognosis of the rituximablyne buphenyls and lytuxixamcins combined fludarabine programmesThe remission rate of toxifxazumab lybsatamstin therapy was 78% (35/45), of which 53% (24 cases) of patients received full remission (CR)interesting, these rates are still higher than the initial prospective trials (2017), and the researchers found that patient slower remission will increase over timeThis can be explained as an extension of the relief time in many patients and may be related to long-lived slurry cellspatients who received remission from rituximab-phenedalimatin treatment, the median duration of the remission after 88 months was still not reached, with an estimated 5-year continuous remission rate of 77%And the safety of the program for advanced malignancies seems to be goodIn contrast, rituximatosis-combined fludarabinthe therapy appears to have a higher risk of long-term adverse reactions